Companies › Addpharma
9 active drug programs in 11 registered trials: 7 Phase 1, 4 Phase 3; Cardiovascular, Metabolic and endocrine, Gastroenterology, Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AD-218 | – | Phase 3 | Mixed Dyslipidemia | – |
| AD-218A | – | Phase 3 | Mixed Dyslipidemia | – |
| AD-227A | – | Phase 3 | Essential Hypertension | – |
| AD-227B | – | Phase 3 | Essential Hypertension | – |
| AD-115A | – | Phase 1 | Gastric Ulcer | – |
| AD-116 | – | Phase 1 | Benign Prostatic Hyperplasia | – |
| AD-228B | – | Phase 1 | Primary Hypercholesterolaemia | – |
| PA-111 | – | Phase 1 | Mixed Dyslipidemia | – |
| PA-111A | – | Phase 1 | Mixed Dyslipidemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06884098 | AD-228B | Phase 1 | Primary Hypercholesterolaemia | Metabolic and endocrine | Apr 2025 |
| NCT06932705 | PA-111 | Phase 1 | Mixed Dyslipidemia | Cardiovascular | May 2025 |
| NCT06932705 | PA-111A | Phase 1 | Mixed Dyslipidemia | Cardiovascular | May 2025 |
| NCT06441630 | AD-227A | Phase 3 | Essential Hypertension | Cardiovascular | Sep 2025 |
| NCT06441630 | AD-227B | Phase 3 | Essential Hypertension | Cardiovascular | Sep 2025 |
| NCT07385235 | AD-115A | Phase 1 | Gastric Ulcer | Gastroenterology | Mar 2026 |
| NCT07385235 | AD-115A | Phase 1 | Gastric Ulcer | Gastroenterology | Mar 2026 |
| NCT05400317 | AD-218 | Phase 3 | Mixed Dyslipidemia | Cardiovascular | Mar 2026 |
| NCT05400317 | AD-218A | Phase 3 | Mixed Dyslipidemia | Cardiovascular | Mar 2026 |
| NCT07444385 | AD-116 | Phase 1 | Benign Prostatic Hyperplasia | Genitourinary | Apr 2026 |
| NCT07444385 | AD-116 | Phase 1 | Benign Prostatic Hyperplasia | Genitourinary | Apr 2026 |
No annotated target.
–
Vaderis Therapeutics HK inno.N Hanlim Pharm. Neurimmune CuraSen Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.